|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Concert_Pharmaceuticals
gptkb:Semma_Therapeutics
gptkb:Exonics_Therapeutics
Acquired Semma Therapeutics
|
|
gptkbp:aims_to
|
transform the lives of people with serious diseases.
|
|
gptkbp:annual_report
|
financial disclosures
|
|
gptkbp:awards
|
gptkb:Innovative_Medicines_Initiative
Best Places to Work
Top Employer
Top 100 Global Innovators
Forbes Most Innovative Companies
|
|
gptkbp:business_model
|
research and development driven
|
|
gptkbp:ceo
|
gptkb:Reshma_Kewalramani
|
|
gptkbp:clinical_trial
|
Phase 3 trials
multiple ongoing trials
Vertex's CFTR modulators
cystic fibrosis therapies
Vertex's drug development
Vertex's gene editing programs
Vertex's gene therapies
Vertex's research pipeline
|
|
gptkbp:collaborates_with
|
academic institutions
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:University_of_Pennsylvania
|
|
gptkbp:community_engagement
|
gptkb:Massachusetts_General_Hospital
gptkb:Cystic_Fibrosis_Foundation
gptkb:Boston_Children's_Hospital
patient advocacy
|
|
gptkbp:develops
|
gptkb:CFTR_modulators
|
|
gptkbp:employees
|
over 2,000
approximately 3,000
|
|
gptkbp:focus
|
gptkb:cystic_fibrosis
gptkb:Cystic_Fibrosis
|
|
gptkbp:focuses_on
|
genetic diseases
|
|
gptkbp:founded
|
gptkb:1989
|
|
gptkbp:founded_by
|
gptkb:Joshua_Boger
gptkb:James_M._Mc_Gowan
Ira L. S. Kauffman
Kevin J. Kinsella
|
|
gptkbp:founded_in
|
gptkb:1989
|
|
gptkbp:founder
|
gptkb:Joshua_Boger
gptkb:James_M._Mc_Gowan
Ira L. S. Kauffman
Kevin J. Kinsella
|
|
gptkbp:global_presence
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
international markets
|
|
gptkbp:has_diversity_initiatives
|
inclusive workplace
|
|
gptkbp:has_partnerships_with
|
other pharmaceutical companies
|
|
gptkbp:has_received
|
numerous awards
|
|
gptkbp:headcount
|
3,000+
|
|
gptkbp:headquartered_in
|
gptkb:Boston,_Massachusetts
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
gptkb:Boston,_Massachusetts,_USA
|
|
gptkbp:healthcare
|
multiple therapies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vertex Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:innovation
|
biopharmaceuticals
|
|
gptkbp:instruction_set
|
multiple drug candidates
gene therapies
multiple investigational therapies
protein replacement therapies
|
|
gptkbp:investment
|
gptkb:public_company
research and development
clinical trials
manufacturing capabilities
|
|
gptkbp:investment_strategy
|
NASDAQ listed
|
|
gptkbp:leadership
|
diverse and inclusive
employee training programs
scientific expertise
business acumen
diverse team
|
|
gptkbp:location
|
gptkb:Europe
gptkb:Asia
gptkb:Canada
gptkb:United_States
|
|
gptkbp:market_cap
|
approximately $50 billion
$50 billion (2021)
|
|
gptkbp:marketing_strategy
|
patient-centric approach
|
|
gptkbp:number_of_employees
|
approximately 2,000
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Pfizer
gptkb:Moderna
gptkb:CRISPR_Therapeutics
Partnership with CRISPR Therapeutics
|
|
gptkbp:partnerships
|
biotech collaborations
|
|
gptkbp:philanthropy
|
gptkb:Vertex_Foundation
support for health initiatives
|
|
gptkbp:product
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:products
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
Cystic fibrosis drugs
Vertex's CFTR modulators
|
|
gptkbp:publications
|
research contributions
|
|
gptkbp:regulatory_compliance
|
FDA regulations
|
|
gptkbp:research_areas
|
genetic diseases
|
|
gptkbp:research_focus
|
gptkb:cystic_fibrosis
gptkb:sickle_cell_disease
gptkb:anemia
rare diseases
chronic diseases
pain
gene editing
small molecule drugs
|
|
gptkbp:revenue
|
$3.4 billion (2020)
$6.2 billion (2020)
$6.2 billion (2022)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:VRTX
|
|
gptkbp:subsidiaries
|
gptkb:Vertex_Pharmaceuticals_(Australia)_Pty_Ltd.
gptkb:Vertex_Pharmaceuticals_(Canada)_Inc.
gptkb:Vertex_Pharmaceuticals_(Europe)_Limited
Vertex Pharmaceuticals (Asia) Limited
|
|
gptkbp:subsidiary
|
gptkb:Vertex_Pharmaceuticals_(Australia)_Pty_Ltd.
gptkb:Vertex_Pharmaceuticals_(Canada)_Inc.
gptkb:Vertex_Pharmaceuticals_(Europe)_Limited
|
|
gptkbp:sustainability_efforts
|
environmental responsibility
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.vrtx.com
vertex.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
gptkb:W3_C
|
|
gptkbp:bfsLayer
|
3
|